Mifamurtide vs HNP-1
Head-to-head comparison of Mifamurtide (Muramyl Tripeptide Phosphatidylethanolamine) and HNP-1 (Human Neutrophil Peptide 1 (Alpha-Defensin 1)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Mifamurtide | HNP-1 |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Muramyl Tripeptide Phosphatidylethanolamine | Human Neutrophil Peptide 1 (Alpha-Defensin 1) |
| Molecular Weight | N/A | 3443 Da |
| Half-Life | 2-4 h | Minutes to hours; protease-sensitive |
| Amino Acids | N/A | 30 |
| Typical Dose | 2 mg/m2 | Research use only; no approved human dose |
| Route | Intravenous | Topical / Research parenteral |
| Purity | ≥98% | ≥98% |
| Studies Count | 150 | 610 |
| Research Status | Clinical | Pre-clinical |
Mifamurtide Benefits
- ✓macrophage-activation
- ✓innate-immune-signaling
- ✓immune-adjuvant-research
- ✓cytokine-response
HNP-1 Benefits
- ✓neutrophil-derived antimicrobial defense
- ✓broad pathogen killing
- ✓immune cell signaling
- ✓mucosal protection
Mifamurtide Dosing
2 mg/m2 IV|2x weekly for 12 weeks|then weekly for 24 weeks in approved regimens
HNP-1 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Mifamurtide Side Effects
- ⚠fever/chills
- ⚠fatigue
- ⚠nausea
HNP-1 Side Effects
- ⚠membrane toxicity at high concentrations
- ⚠short in vivo stability
- ⚠potential inflammation amplification
Research Overview
Mifamurtide
Mifamurtide has substantial literature as an innate immune activator and is an approved oncology adjunct in some regions. Research centers on NOD-like receptor signaling, macrophage activation, and downstream cytokine effects.
HNP-1
HNP-1 has been studied as a key component of neutrophil-mediated host defense against bacteria, fungi, and some enveloped viruses. Literature also reports immunomodulatory effects, including impacts on chemotaxis, cytokine release, and barrier defense.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.